Clinical Research: Phase 1 - Phase 4
Drug Development & Delivery: Navigating the Evolving Landscape of Rare Cancer Trials
Rare cancers account for 27% of all new cancer diagnoses in the US and 22% of all new cancer diagnoses in the EU. With the shift toward grouping cancer based on molecular subtypes rather than by location and tissue type, some common cancers are now categorized as groups of rare cancers. For example, melanoma as...